Anaptys (ANAB) Q2 2026 Financial Results Summary
QuoteReporter
AnaptysBio (ANAB) Q2 2026: Strong Growth in Jemperli Sales — Positive Outlook
AnaptysBio, Inc. (Nasdaq: ANAB) reported its financial results for the second quarter and transitional fiscal year ended June 30, 2026, showcasing a significant increase in revenue driven by Jemperli sales. The company achieved global net sales of $331 million for the three months ended June 30, 2026, representing a 26% year-over-year growth. For the six months ended June 30, 2026, global net sales reached $644 million, reflecting a robust 34% increase compared to the same period last year.
This quarter's performance is a positive development for shareholders, as the substantial growth in Jemperli sales indicates strong market demand and effective commercialization strategies. The increase in revenue is not only a testament to the product's success but also positions AnaptysBio favorably for future growth, particularly with upcoming regulatory milestones.
Key Financial Metrics:
- Global Net Sales (Q2 2026): $331 million, up $68 million or +26% YoY
- Global Net Sales (6M 2026): $644 million, up $164 million or +34% YoY
- Collaboration Revenue (Q2 2026): $27.5 million, up from $22.3 million in Q2 2025
- Net Income from Continuing Operations (Q2 2026): $177.3 million, compared to $5.7 million in Q2 2025
- Basic Net Income per Share (Q2 2026): $6.06, compared to $0.20 in Q2 2025
Operational Highlights:
- AnaptysBio continues to expect to achieve over $390 million in annualized Jemperli royalties by 2029, based on GSK’s peak monotherapy sales guidance of over $2.7 billion.
- The company reported a benefit for income taxes of $181.5 million for the six months ended June 30, 2026, primarily due to the release of the valuation allowance on deferred tax assets.
- General and administrative expenses increased to $16.0 million for Q2 2026, up from $4.0 million in Q2 2025, largely due to legal costs associated with the separation from First Tracks Biotherapeutics and ongoing litigation with GSK and Tesaro.
Shareholder Returns and Future Guidance:
AnaptysBio has not repurchased any shares under its $100 million Stock Repurchase Plan, which is set to expire on December 31, 2026. The company’s cash, cash equivalents, and investments totaled $164.1 million as of June 30, 2026, down from $211.6 million at the end of 2025, primarily due to operating activities.
Looking ahead, investors should closely monitor the anticipated FDA action date of February 2027 for Jemperli in the treatment of untreated stage II/III dMMR/MSI-H locally advanced rectal cancer. Additionally, the upcoming judgement in the litigation with GSK and Tesaro, expected in Q4 2026 or Q1 2027, could significantly impact the company's strategic direction and financial outlook.
Conclusion:
Overall, AnaptysBio's Q2 2026 results reflect a strong performance driven by Jemperli's sales growth, positioning the company well for future opportunities. The upcoming regulatory decisions and litigation outcomes will be critical catalysts for the stock, making it an important period for investors to watch.
Note: The following tables present amounts in thousands.
| AnaptysBio, Inc. Consolidated Statements of Operations and Comprehensive Loss (in thousands, except per share data) | Three Months Ended 2026 June | Three Months Ended 2025 June | Six Months Ended 2026 June | Six Months Ended 2025 June |
|---|---|---|---|---|
| Collaboration Revenue | $27,400 | $22,200 | $53,000 | $50,000 |
| Research and Development Expenses | $(2,700) | $(1,400) | $(2,000) | $(1,000) |
| General and Administrative Expenses | $16,000 | $3,984 | $23,000 | $8,200 |
| Total Operating Expenses | $13,300 | $2,536 | $20,000 | $6,500 |
| Income from Operations | $14,100 | $19,700 | $32,000 | $43,000 |
| Interest Income | $1,486 | $2,102 | $3,200 | $5,400 |
| Sublease Income | $526 | — | $526 | — |
| Non-operating Expense for the Sale of Future Royalties | $(20,000) | $(19,000) | $(41,000) | $(37,000) |
| Other (Expense) Income, Net | $(1) | $3,544 | $(1) | $5,400 |
| Total Other (Expense) Income, Net | $(18,000) | $(13,000) | $(37,000) | $(26,000) |
| (Loss) Income Before Income Taxes | $(4,100) | $5,767 | $(5,000) | $16,000 |
| Benefit (Provision) for Income Taxes | $181,000 | $(39) | $181,000 | $(83) |
| Income from Continuing Operations | $177,000 | $5,728 | $176,000 | $16,000 |
| Income (Loss) from Discontinued Operations, Net of Tax | $6,563 | $(44,000) | $(45,000) | $(94,000) |
| Net Income (Loss) | $183,000 | $(38,000) | $131,000 | $(78,000) |
| Basic Net Income (Loss) per Share from Continuing Operations | $6.06 | $0.20 | $6.28 | $0.55 |
| Basic Net Income (Loss) per Share from Discontinued Operations | $0.22 | $(1.54) | $(1.60) | $(3.25) |
| Basic Net Income (Loss) per Share | $6.28 | $(1.34) | $4.52 | $(2.70) |
| Diluted Net Income (Loss) per Share from Continuing Operations | $5.11 | $0.19 | $5.11 | $0.53 |
| Diluted Net Income (Loss) per Share from Discontinued Operations | $0.18 | $(1.49) | $(1.55) | $(3.13) |
| Diluted Net Income (Loss) per Share | $5.11 | $(1.30) | $3.50 | $(2.60) |
| Weighted Average Number of Shares Outstanding - Basic | 29,200 | 28,800 | 28,000 | 29,000 |
| Weighted Average Number of Shares Outstanding - Diluted | 35,900 | 29,800 | 37,000 | 30,000 |
| AnaptysBio, Inc. Consolidated Balance Sheets (in thousands, except par value data) | June 30, 2026 | December 31, 2025 |
|---|---|---|
| ASSETS | ||
| Current assets: Cash and cash equivalents | $133,826 | $138,196 |
| Receivables from collaborative partners | $25,634 | $33,850 |
| Short-term investments | $30,317 | $73,442 |
| Prepaid expenses and other current assets | $8,650 | — |
| Current assets of discontinued operations | — | $104,762 |
| Total current assets | $198,427 | $350,250 |
| Property and equipment, net | $102 | $111 |
| Deferred tax asset | $106,639 | — |
| Operating lease right-of-use assets | $11,560 | $12,519 |
| Other long-term assets | $256 | $256 |
| Non-current assets of discontinued operations | — | $1,259 |
| Total assets | $316,984 | $364,395 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) | ||
| Current liabilities: Accounts payable | $4,394 | $3,871 |
| Accrued expenses | $28,798 | $32,674 |
| Current portion of operating lease liability | $2,161 | $2,080 |
| Total current liabilities | $35,353 | $38,625 |
| Liability related to sale of future royalties | $256,493 | $276,528 |
| Long-term taxes payable | $3,619 | — |
| Operating lease liability, net of current portion | $10,934 | $12,032 |
| Stockholders’ equity: Preferred stock, $0.001 par value, 10,000 shares authorized and no shares, issued or outstanding at June 30, 2026 and December 31, 2025, respectively | — |
DisclaimerThe content on MarketsFN.com is provided for educational and informational purposes only. It does not constitute financial advice, investment recommendations, or trading guidance. All investments carry risk and past performance does not guarantee future results. You are solely responsible for your investment decisions and should conduct independent research and consult a qualified financial advisor before acting. MarketsFN.com and its authors are not liable for any losses or damages arising from the use of this information. Related Articles Trending Stocks Abivax SA (ABVX) H1 2026 Financial ResultsAbivax (ABVX) Q1 2026: Significant Net Loss Increase — Disappointing Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq – ABVX) reported a net loss of €165.9 million for the first half of 2026, an increase of €65.1 million or +64.5% compared to a net loss of €100.8 million in the same period... QuoteReporter 3 minSep 22, 2026  Trending Stocks Aeluma (ALMU) Q4 2026 Financial Results SummaryAeluma, Inc. (ALMU) Q4 2026: Revenue Decline and Increased Losses — Disappointing Quarter Aeluma, Inc. (NASDAQ: ALMU) reported its fourth quarter and full fiscal year 2026 financial results, revealing a significant decline in revenue and an increase in net losses compared to the previous year.... QuoteReporter 3 minSep 16, 2026  Trending Stocks Lennar Corporation (LEN) Financial Results SummaryLennar Corporation (LEN) Q3 2026: Earnings Decline Amid Market Challenges — Disappointing Quarter Lennar Corporation (NYSE: LEN) reported its third-quarter results for 2026, revealing a significant decline in earnings compared to the previous year. Net earnings attributable to Lennar were $284... QuoteReporter 4 minSep 16, 2026 |